[Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005069:Evaluation Studies as Topic; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011989:Receptors, Thyrotropin / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
D013956:Antithyroid Agents; D015415:Biomarkers; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; D008713:Methimazole
Przeciwciała przeciw receptorom TSH (TRAb) jako wskaźnik w prognozowaniu skuteczności leczenia tiamazolem choroby Gravesa-Basedowa.